Literature DB >> 24692108

Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.

David J Sher1, Matthew Koshy, Michael J Liptay, Mary Jo Fidler.   

Abstract

BACKGROUND: Definitive chemoradiotherapy is a core treatment modality for patients with stage III non-small cell lung cancer (NSCLC). Although radiotherapy (RT) technologies have advanced dramatically, to the authors' knowledge relatively little is known regarding the importance of irradiation technique on outcome, particularly given the competing risk of distant metastasis. The National Cancer Data Base was used to determine predictors of overall survival (OS) in patients with AJCC stage III NSCLC who were treated with chemoradiotherapy, focusing on the importance of conformal RT (CRT).
METHODS: Patients with stage III NSCLC who were treated with chemoradiotherapy between 2003 and 2005 in the National Cancer Data Base were included. RT technique was defined as conventional, 3-dimensional-conformal, or intensity-modulated RT (IMRT), the latter 2 combined as CRT. Cox proportional hazards regression was performed for univariable and multivariable analyses of OS.
RESULTS: The median, 3-year, and 5-year survival outcomes for the 13,292 patients were 12.9 months, 19%, and 11%, respectively. The 3-year and 5-year survival probabilities of patients receiving CRT versus no CRT were 22% versus 19% and 14% versus 11%, respectively (P < .0001). On multivariable analysis, CRT was found to be significantly associated with improved OS (hazards ratio, 0.89). This effect was confirmed on sensitivity analyses, including restricting the cohort to minimum 6-month survivors, young patients with stage IIIA disease, and propensity score-matching. Institutional academic status and patient volume were not found to be associated with OS.
CONCLUSIONS: CRT was found to be independently associated with a survival advantage. These results reflect the importance of optimal locoregional therapy in patients with stage III NSCLC and provide motivation for further study of advanced RT technologies in patients with NSCLC.
© 2014 American Cancer Society.

Entities:  

Keywords:  chemoradiotherapy; conformal radiotherapy; health services research; non-small cell lung cancer (NSCLC)

Mesh:

Year:  2014        PMID: 24692108     DOI: 10.1002/cncr.28677

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.

Authors:  Jian He; Yan Huang; Yixing Chen; Shiming Shi; Luxi Ye; Yong Hu; Jianying Zhang; Zhaochong Zeng
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis.

Authors:  Matthew Koshy; Renuka Malik; Mike Spiotto; Usama Mahmood; Ralph Weichselbaum; David Sher
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

3.  Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.

Authors:  Jingbo Wang; Zongmei Zhou; Jun Liang; Qinfu Feng; Zefen Xiao; Zhouguang Hui; Xiaozhen Wang; Jima Lv; Dongfu Chen; Hongxing Zhang; Zhe Ji; Jianzhong Cao; Lipin Liu; Wei Jiang; Yu Men; Cai Xu; Jiangrong Dai; Weibo Yin; Luhua Wang
Journal:  Oncologist       Date:  2016-09-14

Review 4.  Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation.

Authors:  Yingming Zhu; Minghuan Li; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-07-11       Impact factor: 4.147

Review 5.  A critical review of recent developments in radiotherapy for non-small cell lung cancer.

Authors:  Sarah Baker; Max Dahele; Frank J Lagerwaard; Suresh Senan
Journal:  Radiat Oncol       Date:  2016-09-06       Impact factor: 3.481

6.  hMOF reduction enhances radiosensitivity through the homologous recombination pathway in non-small-cell lung cancer.

Authors:  Nan Li; Guang-Wei Tian; Ling-Rong Tang; Guang Li
Journal:  Onco Targets Ther       Date:  2019-04-23       Impact factor: 4.147

7.  Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.

Authors:  Wenya Su; Wenlu Xiao; Lujun Chen; Qi Zhou; Xiao Zheng; Jingfang Ju; Jingting Jiang; Zhigang Wang
Journal:  Onco Targets Ther       Date:  2019-10-03       Impact factor: 4.147

8.  Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database.

Authors:  Eric D Miller; James L Fisher; Karl E Haglund; John C Grecula; Meng Xu-Welliver; Erin M Bertino; Kai He; Peter G Shields; David P Carbone; Terence M Williams; Gregory A Otterson; Jose G Bazan
Journal:  Radiat Oncol       Date:  2018-10-05       Impact factor: 3.481

9.  Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.

Authors:  Wenjie Ni; Jinsong Yang; Wei Deng; Zefen Xiao; Zongmei Zhou; Hongxing Zhang; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Tao Zhang; Nan Bi; Lei Deng; Wenqing Wang
Journal:  BMC Cancer       Date:  2020-02-22       Impact factor: 4.430

10.  Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol.

Authors:  Xiao Chang; Lei Deng; Wenjie Ni; Chen Li; Weiming Han; Lin-Rui Gao; Shijia Wang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Nan Bi; Jima Lv; Shugeng Gao; Yousheng Mao; Qi Xue; Zefen Xiao
Journal:  BMC Cancer       Date:  2020-09-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.